France, Germany, Italy and Poland have urged European Commission Vice President Margrethe Vestager to stop dragging her feet on competition law reforms that they insist are needed to forge European champions to rival China and the US.
For more than a year, Paris and Berlin have been pushing for new EU antitrust rules after Vestager blocked a mega merger in the rail sector between France’s Alstom and Germany’s Siemens. They reckon that deal would have created the sort of corporate giant that Europe needs, an Airbus of the train sector, while Vestager argued that the merger would have harmed European consumers.
After months of resisting the Franco-German onslaught, Vestager unexpectedly announced in December that she would review the rule book, but then declined to map out any timeframe, reported Politico.
Paris, Berlin, Rome and Warsaw, four of the EU’s political heavyweights, have now taken the unusually confrontational step of telling Vestager to hurry up and produce her action plan on various competition reforms within weeks. Their letter, dated February 4 and obtained by Politico, comes amid a major European strategic shift toward a centralized industrial policy, and only weeks before the Commission is due to launch its own industrial strategy agenda on March 10.
Featured News
Top Antitrust Expert Joins Cravath from Paul Weiss
Jan 21, 2025 by
CPI
CMA Chief Removed as UK Government Targets Regulatory Overhaul
Jan 21, 2025 by
CPI
Court Denies Dismissal in Crab Price-Fixing Lawsuit
Jan 21, 2025 by
CPI
TikTok Stays Online for Now: Trump Floats US Ownership Deal
Jan 21, 2025 by
CPI
Hong Kong Watchdog Unveils Compliance Tool for Small Businesses
Jan 21, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Pharmacy Benefit Managers
Jan 20, 2025 by
CPI
Untangling the PBM Mess
Jan 20, 2025 by
Kent Bernard
Using Data, Not Anecdotes, to Analyze Criticisms of Pharmacy Benefit Managers
Jan 20, 2025 by
Dennis Carlton
Vertical Integration and PBMs: What, Me Worry?
Jan 20, 2025 by
Lawton Robert Burns & Bradley Fluegel
The Economics of Benefit Management in Prescription-Drug Markets
Jan 20, 2025 by
Casey B. Mulligan